3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
37
Lymphoma
27
Urinary Bladder Neoplasms
9
Melanoma
7
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Skin Neoplasms
2
Oligodendroglioma
2
Neurofibromatosis 1
2
Neoplasms
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia
2
HIV Infections
2
Glioma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Urothelial Carcinoma of the Bladder
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Survival Without Progression
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Optic Nerve Glioma
1
Neurofibroma, Plexiform
1
Interventions
Rituximab
187
Cyclophosphamide
174
Etoposide
94
Peripheral Blood Stem Cell Transplantation
90
Vincristine
89
Prednisone
80
Doxorubicin
79
Filgrastim
75
fludarabine phosphate
60
Radiotherapy
56
Mycophenolic Acid
41
Melphalan
41
Cytarabine
41
Busulfan
40
Cyclosporine
39
Methotrexate
37
Whole-Body Irradiation
36
Tacrolimus
35
Carmustine
34
Ifosfamide
28
Lenalidomide
27
Granulocyte Colony-Stimulating Factor
27
Antilymphocyte Serum
27
Gemcitabine
25
Carboplatin
25
Methylprednisolone
24
ibritumomab tiuxetan
23
Bortezomib
22
Dexamethasone
21
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large B-Cell, Diffuse
×
Vinblastine
×
Clear all
NCT01148446
2010-06-22
ANZINTER3
Fondazione Italiana Linfomi - ETS
Phase 3
Completed
226 enrolled